Johnson & Johnson’s Tremfya gains FDA approval for Crohn’s disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints.
FDA Approves Johnson & Johnson’s Tremfya For Crohn’s Disease
Where Today's News Shapes Tomorrow
